Noam Kirson

Education
Ph.D., economics, Harvard University; B.A., philosophy, political science, and economics, Hebrew University
Summary of Experience
Dr. Kirson is an applied health economist with extensive experience in health economics and outcomes research (HEOR), strategy and market access, and complex litigation matters. He specializes in the application of advanced statistical methods to the analysis of a variety of real-world and clinical data, as well as to the development of advanced modeling tools. He has worked closely with many different stakeholders in the health care industry, including biopharmaceutical and device manufacturers, payers, government agencies, leading law firms, and academic experts. Dr. Kirson has managed numerous HEOR and strategy projects, including novel cost-effectiveness analyses, submissions to health technology assessment (HTA) organizations, the design of outcomes-based contracts, the analysis of pharmaceutical pricing, burden-of-illness studies, comparative-effectiveness research, and budget impact assessments. In the regulatory context, he has supported a successful 510(k) pre-market submission to the US Food and Drug Administration (FDA) on behalf of a medical device manufacturer, including the presentation of statistical analyses to an FDA advisory panel. In litigation, Dr. Kirson’s case work has included the evaluation of antitrust matters in the health care sector and the assessment of issues pertaining to the False Claims Act. His work has resulted in numerous conference presentations and peer-reviewed publications, including in Health Affairs, Alzheimer’s & Dementia, Diabetes Care, Critical Care Medicine, the Journal of Clinical Psychiatry, and various pharmacoeconomic journals. He has also published in non-academic outlets such as Health Affairs Blog, STAT, and Law360. Dr. Kirson is the president of the ISPOR Boston Regional Chapter, and serves on the editorial board of the journal Pharmacoeconomics Open.
-
Disease Progression and Longitudinal Clinical Outcomes of Lewy Body Dementia in the Nacc Database
Neurology and Therapy, 2023
2023Chandler J, Georgieva M, Desai U, Kirson N, Lane H, Cheung HC, Westermeyer B, Biglan K
HEOR, Epidemiology & Market Access -
Health Care Resource Utilization by Patients with Alagille Syndrome
The Journal of Pediatrics, 2023
2023Ebel NH, Goldstein A, Howard R, Mogul DB, Marden JR, Anderson A, Gaburo K, Kirson N, Rosenthal P
HEOR, Epidemiology & Market Access -
Costs of Pediatric Liver Transplantation among Commercially- and Medicaid-Insured Patients with Cholestasis in the United States
Liver Transplantation, 2023
2023Miloh T, Goldstein A, Howard R, Mogul DB, Marden JR, Anderson A, Gaburo K, Kirson N, Rosenthal P
HEOR, Epidemiology & Market Access -
Direct health care costs associated with COVID-19 in the United States
Journal of Managed Care & Specialty Pharmacy, 2022
2022DeMartino J, Swallow E, Goldschmidt D, Yang K, Viola M, Radtke T, Kirson N
HEOR, Epidemiology & Market Access -
Maralixibat Treatment Response in Alagille Syndrome Is Associated with Improved Health-Related Quality of Life
The Journal of Pediatrics, 2022
2022Kamath BM, Goldstein A, Howard R, Garner W, Vig P, Marden JR, Billmyer E, Anderson A, Kirson N, Jacquemin E, Gonzales E
HEOR, Epidemiology & Market Access -
Real-world treatment, dosing, and discontinuation patterns among patients treated with pegvaliase for phenylketonuria: Evidence from dispensing data
Molecular Genetics and Metabolism Reports, 2022
2022Lah M, Cook K, Aparna Gomes D, Liu S, Tabatabaeepour N, Kirson N, Chen E, Lindstrom K, Bulloch Whitehall K, Van Backle J, Burton BK
HEOR, Epidemiology & Market Access -
Physician perceptions of drug utilization management: Results of a national survey
PLOS One, 2022
2022Edwards ML, Yin PT, Kuehn M, Bratti K, Kirson N, Jena AB, Howell S
HEOR, Epidemiology & Market Access -
The societal economic value of COVID-19 vaccines in the United States
Journal of Medical Economics, 2022
2022Kirson N, Swallow E, Lu J, Mesa-Frias M, Bookhart B, Maynard J, Shivdasani Y, Lefebvre P
HEOR, Epidemiology & Market Access -
Increasing COVID-19 vaccination in the United States: projected impact on cases, hospitalizations, and deaths by age and racial group
Public Health, 2022
2022Kirson N, Swallow E, Lu J, Foroughi C, Bookhart B, DeMartino JK, Maynard J, Shivdasani Y, Eid D, Lefebvre P
HEOR, Epidemiology & Market Access -
Assessment of the Impact of a Meningitis/Encephalitis Panel on Hospital Length of Stay: A Systematic Review and Meta-Analysis
Antibiotics, 2022
2022Hueth KD, Thompson-Leduc P, Totev TI, Milbers K, Timbrook TT, Kirson N, Hasbun R
HEOR, Epidemiology & Market Access -
The Physician and Administrator-Reported Cost of Drug Utilization Management to Physician Practices: A Cross-Sectional Survey
PharmacoEconomics, 2022
2022Edwards ML, Yin PT, Kuehn M, Bratti K, Kirson N, Jena A, Howell S
HEOR, Epidemiology & Market Access -
The experience of a severe hypoglycaemic event from the perspective of people with diabetes and their caregivers: "What am I going to do?"
Diabetic Medicine, 2022
2022Stuckey HL, Desai U, King SB, Popadic L, Levinson W, Kirson NY, Hankosky ER, Mitchell B
HEOR, Epidemiology & Market Access -
Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease 'OFF' episodes
Journal of Comparative Effectiveness Research, 2022
2022Thach A, Zichlin ML, Kirson N, Yang K, Gaburo K, Pappert E, Mehta D, Williams GR
HEOR, Epidemiology & Market Access -
Epidemiology and economic burden of Lewy body dementia in the United States
Current Medical Research and Opinion, 2022
2022Desai U, Chandler J, Kirson N, Georgieva M, Cheung HC, Westermeyer B, Lane H, Biglan K
HEOR, Epidemiology & Market Access -
Assessing Barriers to Access and Equity for COVID-19 Vaccination in the US
BMC Public Health, 2022
2022Kuehn M, LaMori J, DeMartino JK, Mesa-Frias M, Doran J, Korrapati L, Bhojwani R, Lefebvre P, Kirson N
HEOR, Epidemiology & Market Access -
The Economic Burden of Schizophrenia in the United States
Journal of Clinical Psychiatry, 2022
2022Kadakia A, Catillon M, Fan Q, Williams GR, Marden JR, Anderson A, Kirson N, Dembek C
HEOR, Epidemiology & Market Access -
Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression
Journal of Comparative Effectiveness Research, 2021
2021Desai U, Kirson NY, Guglielmo A, Le HH, Spittle T, Tseng-Tham J, Shawi M, Sheehan JJ
HEOR, Epidemiology & Market Access -
Outcomes and resource use of patients with large hemispheric infarction and cerebral edema: analysis of real-world data
Current Medical Research and Opinion, 2021
2021Chen SY, Thompson-Leduc P, Sawyer Jr RN, Fakih I, Cheung HC, Macheca M, Kirson NY, Torbey M
HEOR, Epidemiology & Market Access -
Cost-Effectiveness of Apomorphine Sublingual Film as an "On-Demand" Treatment for "OFF" Episodes in Patients with Parkinson's Disease
Journal of Health Economics and Outcomes Research, 2021
2021Thach A, Kirson N, Zichlin ML, Dieye I, Pappert E, Williams GR
HEOR, Epidemiology & Market Access -
Decreased antibiotic exposure using a procalcitonin protocol for respiratory infections and sepsis in US community hospitals (ProCommunity)
Current Medical Research and Opinion, 2021
2021DeSear KE, Thompson-Leduc P, Van Schooneveld TC, Kirson N, Chritton JJ, Ie S, Cheung HC, Ou S, Zimmer L, Schuetz P
HEOR, Epidemiology & Market Access -
Financing Drug Innovation in the US: Current Framework and Emerging Challenges
Pharmacoeconomics, 2020
2020Cutler C, Kirson N, Long G
HEOR, Epidemiology & Market Access -
Disease severity at the time of initial cognitive assessment is related to prior health-care resource use burden
Alzheimer's & Dementia, 2020
2020Desai U, Kirson NY, Lu Y, Bruemmer V, Andrews JS
HEOR, Epidemiology & Market Access -
ProCommunity: procalcitonin use in real-world US community hospital settings
Current Medical Research and Opinion, 2020
2020DeSear KE, Thompson-Leduc P, Kirson N, Chritton JJ, Ie S, Van Schooneveld TC, Cheung HC, Ou S, Schuetz P
HEOR, Epidemiology & Market Access -
-
Temporal and Geographic Variation in the Incidence of Alzheimer’s Disease Diagnosis in the US between 2007 and 2014
Journal of the American Geriatrics Society, December 3, 2019
2019Kirson N, Meadows ES, Desai U, Smith BP, Cheung HC, Zuckerman P, Matthews BR
HEOR, Epidemiology & Market Access -
Mild traumatic brain injury in the United States: demographics, brain imaging procedures, health-care utilization and costs
Brain Injury, 2019
2019Pavlov V, Thompson-Leduc P, Zimmer L, Wen J, Shea J, Beyhaghi H, Toback S, Kirson N, Miller M
HEOR, Epidemiology & Market Access -
Trends in health service use and potentially avoidable hospitalizations before Alzheimer's disease diagnosis: A matched, retrospective study of US Medicare beneficiaries
Alzheimer's & Dementia, 2019
2019Desai U, Kirson NY, Ye W, Mehta NR, Wen J, Andrews JS
HEOR, Epidemiology & Market Access -
Economic and clinical benefits of early identification of acute kidney injury using a urinary biomarker
Journal of Medical Economics, 2019
2019Berdugo MA, Kirson NY, Zimmer L, Beyhaghi H, Toback S, Scarpati LM, Stone MN, Dember R, Tseng-Tham J, Wen J, Miller M
HEOR, Epidemiology & Market Access -
Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials
Alzheimer's & Dementia, 2019
2019Andrews JS, Desai U, Kirson NY, Zichlin ML, Ball DE, Matthews BR
HEOR, Epidemiology & Market Access -
Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease
Journal of Alzheimer's Disease. Nov 14 2018;61(1):295-307
2018Kirson NY, Scott Andrews J, Desai U, King SB, Schonfeld S, Birnbaum HG, Ball DE, Kahle-Wrobleski K
HEOR, Epidemiology & Market Access -
Procalcitonin guidance in patients with lower respiratory tract infections: a systematic review and meta-analysis
Clinical Chemistry and Laboratory Medicine. May 1 2018
2018Hey J, Thompson-Leduc P, Kirson NY, Zimmer L, Wilkins D, Rice B, Iankova I, Krause A, Schonfeld SA, DeBrase CR, Bozzette S, Schuetz P
HEOR, Epidemiology & Market Access -
Are Payers Ready to Address the Financial Challenges Associated with Gene Therapy?
Health Affairs, June 28, 2018
2018Ciarametaro M, Long G, Johnson M, Kirson N, Dubois R
HEOR, Epidemiology & Market Access -
-
Reliability of coded data to identify earliest indications of cognitive decline, cognitive evaluation and Alzheimer's disease diagnosis: a pilot study in England
BMJ Open. Mar 22 2018;8(3):e019684
2018Dell'Agnello G, Desai U, Kirson NY, Wen J, Meiselbach MK, Reed CC, Belger M, Lenox-Smith A, Martinez C, Rasmussen J
HEOR, Epidemiology & Market Access -
The Economic Burden of Abuse of Prescription Opioids: A Systematic Literature Review from 2012 to 2017
Applied Health Economics and Health Policy. 2018 Oct;16(5):609-632
2018Reinhart M, Scarpati LM, Kirson NY, Patton C, Shak N, Erensen JG
HEOR, Epidemiology & Market Access -
Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes
Diabetes Care. 2018 Oct;41(10):2096-2104
2018Desai U, Kirson NY, Kim J, Khunti K, King S, Trieschman E, Hellstern M, Hunt PR, Mukherjee J
HEOR, Epidemiology & Market Access -
Reliability of coded data to identify earliest indications of cognitive decline, cognitive evaluation and Alzheimer's disease diagnosis: a pilot study in England
BMJ Open. 2018 Mar 22;8(3):e019684
2018Dell'Agnello G, Desai U, Kirson NY, Wen J, Meiselbach MK, Reed CC, Belger M, Lenox-Smith A, Martinez C, Rasmussen J
HEOR, Epidemiology & Market Access -
Consider Value Vs. Budget Impact in Mass. Drug Prices
Law360, September 29, 2017
HEOR, Epidemiology & Market Access
2017 -
Functional limitations and health care resource utilization for individuals with cognitive impairment without dementia: Findings from a United States population-based survey
Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 2017;6:65-74
2017Andrews JS, Desai U, Kirson NY, Enloe CJ, Ristovska L, King S, Birnbaum HG, Fleisher AS, Ye W, Kahle-Wrobleski K
HEOR, Epidemiology & Market Access -
The Economic Burden of Opioid Abuse: Updated Findings
Journal of Managed Care and Specialty Pharmacy. Apr 2017;23(4):427-445
2017Kirson NY, Scarpati LM, Enloe CJ, Dincer AP, Birnbaum HG, Mayne TJ
HEOR, Epidemiology & Market Access -
Opioid abuse: A detailed examination of cost drivers over a 24-month follow-up period
Journal of Managed Care and Specialty Pharmacy. 01 Nov 2017;23(11):1110-1115
2017Scarpati LM, Kirson NY, Jia ZB, Wen J, Howard J
HEOR, Epidemiology & Market Access -
Drivers of excess costs of opioid abuse among a commercially insured population
American Journal of Managed Care. May 2017;23(5):276-282
2017Scarpati LM, Kirson NY, Zichlin ML, Jia ZB, Birnbaum HG, Howard JC
HEOR, Epidemiology & Market Access -
Insurance Switching and Mismatch Between the Costs and Benefits of New Technologies
The American Journal of Managed Care, December 2017
2017Cutler D, Ciarametaro M, Long G, Kirson N, Dubois R
HEOR, Epidemiology & Market Access -
Efficacy and Safety of Procalcitonin Guidance in Patients With Suspected or Confirmed Sepsis: A Systematic Review and Meta-Analysis
Critical Care Medicine. Dec 21 2017
2017Iankova I, Thompson-Leduc P, Kirson NY, Rice B, Hey J, Krause A, Schonfeld SA, DeBrase CR, Bozzette S, Schuetz P
HEOR, Epidemiology & Market Access -
Basal Insulin Persistence, Associated Factors, and Outcomes after Treatment Initiation: A Retrospective Database Study Among People with Type 2 Diabetes Mellitus in Japan
Diabetes Therapy. Feb 2017;8(1):149-166
2017Hadjiyianni I, Desai U, Suzuki S, Ivanova JI, Cao D, Kirson NY, Chida D, Enloe C, Birnbaum HG, Perez-Nieves M
HEOR, Epidemiology & Market Access -
Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US
Current Medical Research and Opinion, 2016 04; 32(4): 669-680. e-pub ahead of print 2015/12/26
2016Perez-Nieves M, Kabul S, Desai U, Ivanova JI, Kirson NY, Cummings AK, Birnbaum HG, Duan R, Cao D, Hadjiyianni I.
HEOR, Epidemiology & Market Access -
Excess Costs Associated with Possible Misdiagnosis of Alzheimer's Disease Among Patients with Vascular Dementia in a UK CPRD Population
Journal of Alzheimer's Disease, 2016 05. doi: 10.3233/JAD-150685
2016Happich M, Kirson NY, Desai U, King S, Birnbaum HG, Reed C, Belger M, Lenox-Smith A, Price D.
HEOR, Epidemiology & Market Access -
The Burden of Undiagnosed Opioid Abuse Among Commercially Insured Individuals
Pain Med. 2015 Apr 30. doi: 10.1111/pme.12768
2015Kirson NY, Shei A, Rice JB, Enloe CJ, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R
HEOR, Epidemiology & Market Access -
Sources of prescription opioids among diagnosed opioid abusers
Curr Med Res Opin. 2015 Apr;31(4):779-84
2015Shei A, Rice JB, Kirson NY, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R
HEOR, Epidemiology & Market Access -
The economic burden of diagnosed opioid abuse among commercially insured individuals
Postgrad Med. 2014 Jul;126(4):53-8
2014Rice JB, Kirson NY, Shei A, Enloe CJ, Cummings AK, Birnbaum HG, Holly P, Ben-Joseph R
HEOR, Epidemiology & Market Access -
Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data
Appl Health Econ Health Policy. 2014 Aug;12(4):435-46
2014Rice JB, Kirson NY, Shei A, Cummings AK, Bodnar K, Birnbaum HG, Ben-Joseph R
HEOR, Epidemiology & Market Access -
Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States
Pain Med. 2014 Sep;15(9):1450-4. doi: 10.1111/pme.12489. Epub 2014 Jul 8
2014Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, Rossiter LF, Michna E
HEOR, Epidemiology & Market Access -
Evolving Brand-Name and Generic Drug Competition May Warrant a Revision of the Hatch-Waxman Act
Health Affairs, 2011, 30(11), 2157-2166
2011Grabowski HG, Kyle M, Mortimer R, Long G, Kirson N
HEOR, Epidemiology & Market Access, Intellectual Property, Strategy, Policy & Analytics -
Direct and indirect costs of patients treated with extended-release oxymorphone HCl or controlled-release oxycodone HCl
J Med Econ. 2011 Oct 28.
2011Kirson N, White A, Birnbaum H, Schiller M, Waldman T, Peterson K, Ben-Joseph R, Berner T, Summers K
HEOR, Epidemiology & Market Access -
Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a U.S. privately insured population
Appl Health Econ Health Policy. 2011 Nov 1;9(6):377-87.
2011Kirson N, Birnbaum H, Ivanova J, Waldman T, Joish V, Williamson T
HEOR, Epidemiology & Market Access -
Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States
Curr Med Res Opin. 2011 Sep;27(9):1763-8.
2011Kirson N, Birnbaum H, Ivanova J, Waldman T, Joish V, Williamson T
HEOR, Epidemiology & Market Access -
Excess costs associated with patients with pulmonary arterial hypertension in a U.S. privately insured population
Appl Health Econ Health Policy. 2011 Sep 1;9(5):293-303.
2011Kirson N, Birnbaum H, Ivanova J, Waldman T, Joish V, Williamson T
HEOR, Epidemiology & Market Access -
Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5 percent
J Med Econ. 2010 Sep;13(3):472-81
2010Kirson N, Ivanova J, Birnbaum H, Kantor E, Amy Puenpatom R, Ben-Joseph R, Summers K
HEOR, Epidemiology & Market Access -
Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5 percent versus gabapentin or pregabalin
J Med Econ. 2010 Sep;13(3):482-91
2010Kirson N, Ivanova J, Birnbaum H, Kantor E, Puenpatom R, Ben-Joseph R, Summers K
HEOR, Epidemiology & Market Access
-
June 8, 2022
First Webinar in Law & Economics Symposium Webinar Series to Focus on Drug Pricing
Event: What Happens Next? Value Assessment, Drug Pricing Policy, and the R&D Pipeline
Host: Analysis Group -
May 7, 2023
Analysis Group HEOR Consultants to Present at ISPOR 2023
Event: ISPOR 2023
Host: ISPOR – The International Society for Pharmacoeconomics and Outcomes Research
-
May 3, 2023
-
March 3, 2023
-
February 13, 2023
-
July 11, 2022
-
Health Care Bulletin Pricing, Litigation, Enforcement: The 2022 Law & Economics Symposium in Review
-
AG Feature Innovation, Drug Pricing, and the Pandemic: A Q&A with Craig Garthwaite
-
Health Care Bulletin Protecting Access, Encouraging Innovation: A Discussion About Drug Pricing
-
Health Care Bulletin New Payment Strategies for Gene Therapy
-
AG Feature More than Dollars and Cents: Prescription Drug Pricing and Value
-
Forum Noam Kirson - Balancing Drug Pricing With Value
-
Health Care Bulletin Abuse-Deterrent Opioids and the Economic Costs of Abuse
-
Health Care Bulletin Assessing the Economic Burden of Alzheimer’s Disease